mRNA-Based Vaccination Drives in Vivo Dendritic Cell Reprogramming and Selective Cytotoxic T Lymphocyte Modulation for Enhanced Antitumor Immunity

Oct 28, 2025ACS nano

mRNA Vaccines Reprogram Immune Cells and Selectively Boost Cancer-Fighting T Cells for Better Tumor Protection

AI simplified

mRNA Technology on OpenScience ↗PubMed ↗DOI ↗

Abstract

Prophylactic vaccination using the VISIT platform resulted in complete tumor rejection in mouse models.

The VISIT strategy involves reprogramming dendritic cells to enhance T cell responses against tumors.
Lipid nanoparticles deliver mRNAs to dendritic cells, promoting the display of tumor antigens and a T cell growth factor.
This approach leads to the activation and expansion of antigen-specific cytotoxic T lymphocytes.
Mice receiving the VISIT vaccination showed long-term immunological memory against tumor rechallenge.
In established cancer models, systemic vaccination significantly inhibited tumor growth and improved T cell responses.
Combining the VISIT vaccination with immune checkpoint inhibitors further increased overall survival in melanoma-bearing mice.

AI simplified

Precisely engineering T cells for targeted tumor recognition and overcoming the insufficiency of antigen-specific T cells in vivo are major challenges in cancer immunotherapy. Here, we present a streamlined strategy termed VISIT (accine-nitiatedelectvecell modulation) that enables spatiotemporal modulation of cytotoxic T lymphocytes (CTLs) through in vivo dendritic cell (DC) reprogramming. This approach employs optimized lipid nanoparticles to preferentially deliver mRNAs to splenic DCs, enabling the simultaneous presentation of tumor antigens and the membrane-bound IL-15/IL-15Rα complex as a T cell booster on the DC surface, thereby promoting antigen-specific CTL activation and expansion while minimizing nonspecific immune activation. Prophylactic vaccination resulted in complete tumor rejection and the establishment of long-term immunological memory, providing effective protection against tumor rechallenge. In mice with established OVA expressing colon carcinoma and aggressive melanoma models, systemic vaccination maximized antigen-specific CTL responses and inhibited tumor growth. When combined with immune checkpoint inhibitors, the treatment exhibited a synergistic effect, further extending overall survival in melanoma-bearing mice. Overall, the VISIT vaccination platform offers an in vivo DC reprogramming approach for developing personalized cancer immunotherapies through precise spatiotemporal modulation of DC-T cell interactions. v i s i T

Full Text

Full text is available at the source.

View full text (PDF) ↗View full text ↗

mRNA-Based Vaccination Drives in Vivo Dendritic Cell Reprogramming and Selective Cytotoxic T Lymphocyte Modulation for Enhanced Antitumor Immunity

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the mrna technology brief

Abstract

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the mrna technology brief